Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here’s Why
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $508.34, moving -1.55% from the previous trading session. The stock’s performance was behind the S&P 500’s daily gain of 0.17%. At the same time, the Dow lost 0.18%, and the tech-heavy Nasdaq gained 0.4%.
Coming into today, shares of the drugmaker had lost 4.43% in the past month. In that same time, the Medical sector gained 0.65%, while the S&P 500 lost 1.29%.
The investment community will be paying close attention to the earnings performance of Vertex Pharmaceuticals in its upcoming release. The company’s earnings per share (EPS) are projected to be $4.84, reflecting a 0.83% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $3.4 billion, up 10.43% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $18.86 per share and a revenue of $13.21 billion, demonstrating changes of +2.5% and +10.08%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for Vertex Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we’ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there’s been a 1.04% fall in the Zacks Consensus EPS estimate. As of now, Vertex Pharmaceuticals holds a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 27.38. Its industry sports an average Forward P/E of 23.81, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.
We can also see that VRTX currently has a PEG ratio of 2. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. By the end of yesterday’s trading, the Medical – Biomedical and Genetics industry had an average PEG ratio of 1.94.
